Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly and HAYA Therapeutics ink a potential $1 billion drug discovery deal to target obesity and metabolic conditions. The multi-year collaboration applies…
Lilly and HAYA will collaborate to find genome targets for obesity using HAYA's full-stack regulatory genome platform to identify tissue-, disease- and…
Wilson Sonsini advised HAYA Therapeutics on patent matters related to its multi-year collaboration with Eli Lilly and Company to discover novel regulatory…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
HAYA Therapeutics announced multi-year collaboration with Eli Lilly applying HAYA's regulatory genome RNA platform to preclinical obesity and metabolic drug discovery. HAYA receives upfront + equity investment and is eligible for up to $1B in preclinical, clinical, and commercial milestones plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / HAYA Therapeutics SA (this deal) | 2024 | $1.0B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2024 deals · Eli Lilly and Company deals · Metabolic deals